Overview

Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers

Status:
COMPLETED
Trial end date:
2025-11-22
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-383 in healthy volunteers
Phase:
PHASE1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Treatments:
lobeglitazone